Friess H, Büchler M, Auerbach B, Weber A, Malfertheiner P, Hammer K, Madry N, Greiner S, Bosslet K, Beger H G
Department of General Surgery, University of Ulm, Germany.
Int J Cancer. 1993 Mar 12;53(5):759-63. doi: 10.1002/ijc.2910530509.
In 59 patients with ductal pancreatic cancer the monoclonal antibody (MAb) BW 494, which detects the CA 494 glycoprotein antigen, was analyzed in comparison with the reference tumor markers CA 19-9 and CEA. Eighty-one patients with non-pancreatic malignancies of the gastrointestinal (GI) tract, 95 with chronic pancreatitis, 124 with benign non-pancreatic GI diseases, 30 with diabetes mellitus (type I or type II) and 114 healthy blood donors served as controls. The sensitivity of pancreatic cancer was 90%, 44% and 90% for CA 19-9, CEA and CA 494, respectively. In chronic pancreatitis, as the most important control population for pancreatic cancer, the specificity was 85%, 72% and 94% for CA 19-9, CEA and CA 494, respectively.
在59例导管腺癌患者中，对检测CA 494糖蛋白抗原的单克隆抗体（MAb）BW 494进行了分析，并与参考肿瘤标志物CA 19-9和癌胚抗原（CEA）作比较。81例胃肠道（GI）非胰腺恶性肿瘤患者、95例慢性胰腺炎患者、124例非胰腺良性GI疾病患者、30例糖尿病（I型或II型）患者及114例健康献血者作为对照。CA 19-9、CEA和CA 494对胰腺癌的敏感性分别为90%、44%和90%。在作为胰腺癌最重要对照人群的慢性胰腺炎患者中，CA 19-9、CEA和CA 494的特异性分别为85%、72%和94%。
